TABLE 1

Characteristics of study patients

VariablesControl groupPlacebo groupRosiglitazone group
n302323
Age (years)69 ± 268 ± 369 ± 2
Male16 (53.3)13 (56.5)12 (52.2)
Patients characteristics
    Family history of IHD14 (46.7)13 (56.5)16 (69.6)
    Hypertension15 (50)11 (47.8)10 (43.5)
    Hypercholesterolemia13 (43.3)10 (43.5)9 (39.1)
    Cigarette smoking12 (40)7 (30.4)8 (34.8)
    Coronary artery disease13 (43.3)14 (60.9)16 (69.6)
    BMI (kg/m2)27.6 ± 228.2 ± 228.9 ± 3
    Systolic blood pressure (mmHg)128 ± 12129 ± 11130 ± 12
    Diastolic blood pressure (mmHg)81 ± 481 ± 482 ± 3
    A1C (%)4.9 ± 1.1*8.1 ± 1.48.2 ± 1.5
    Blood glucose (mmol/l)6 ± 0.9*9.7 ± 1.49.6 ± 1.3
    Insulin (μU/ml)8.06 ± 3.3*10.6 ± 2.410.8 ± 2.7
    HOMA-IR2.15 ± 0.9*4.57 ± 1.34.61 ± 1.3
    CRP (mg/dl)0.86 ± 0.09*1.22 ± 0.081.19 ± 0.09
    Total cholesterol (mmol/l)5.64 ± 0.095.63 ± 0.095.67 ± 0.10
    HDL cholesterol (mmol/l)1.26 ± 0.101.22 ± 0.081.21 ± 0.09
    Triglycerides (mmol/l)1.94 ± 0.331.95 ± 0.311.97 ± 0.34
    Stenosis severity (%)75.5 ± 4.976.4 ± 4.576.2 ± 3.8
    Macrophage-rich areas (%)5 ± 2*24 ± 514 ± 6*
    T-cells per mm2 section area15 ± 7*70 ± 1341 ± 12*
    HLA-DR (%)12 ± 3*31 ± 519 ± 6*
Active therapy
    Aspirin24 (80)21 (91.3)20 (86.9)
    Warfarin2 (6.6)1 (4.3)1 (4.3)
    β-Blocker7 (23.3)5 (21.7)5 (21.7)
    Calcium-channel blocker3 (10)4 (17.4)3 (13.1)
    Statin20 (66.6)17 (73.9)16 (69.6)
    ACE inhibitor16 (53.3)14 (60.9)12 (52.1)
    Diuretic agent9 (30)6 (26.1)7 (30.4)
    AT-2 antagonist14 (46.6)12 (52.1)11 (48.7)
    Insulin16 (69.6)17 (73.9)
    Sulfonylureas8 (34.8)7 (30.4)
    Metformin6 (26.1)5 (21.7)
  • Data are means ± SD or n (%).

  • *

    * P < 0.05 vs. the placebo group;

  • P < 0.05 vs. the rosiglitazone group. IHD, ischemic heart disease.